How have INTI shares performed in 2024?

Inhibitor Therapeutics' stock was trading at $0.0920 on January 1st, 2024. Since then, INTI shares have decreased by 25.5% and is now trading at $0.0685. View the best growth stocks for 2024 here .

Are investors shorting Inhibitor Therapeutics?

Inhibitor Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 500 shares, an increase of 400.0% from the March 15th total of 100 shares. Based on an average daily volume of 37,200 shares, the days-to-cover ratio is presently 0.0 days. View Inhibitor Therapeutics' Short Interest .

When is Inhibitor Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our INTI earnings forecast .

How were Inhibitor Therapeutics' earnings last quarter?

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) announced its earnings results on Friday, March, 29th. The company reported ($0.01) earnings per share (EPS) for the quarter.

How do I buy shares of Inhibitor Therapeutics?

Shares of INTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:INTI

Inhibitor Therapeutics (INTI) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free INTI Stock Alerts

$0.07

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.07
▼
$0.07
50-Day Range: $0.05
▼
$0.08
52-Week Range: $0.01
▼
$0.30

Volume: N/A
Average Volume: 9,224 shs
Market Capitalization: $11.78 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines SEC Filings Short Interest

Get Inhibitor Therapeutics alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Inhibitor Therapeutics Stock (OTCMKTS:INTI)

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.

INTI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INTI Stock News Headlines

April 15, 2024 | finance.yahoo.com

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Pipeline Research Report 2024: Drugs in Development, Therapeutics Scenario and Growth Prospects

April 8, 2024 | msn.com

Saruparib demonstrates early efficacy in breast cancers with DNA repair defects in Phase I/II trial

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

April 3, 2024 | finance.yahoo.com

Watchmaker Genomics Announces Launch of Cost-effective RNase Inhibitor for Single-cell, Single-nuclei, and Pathogen Detection Applications

March 14, 2024 | finance.yahoo.com

Janus Kinase (JAK) Inhibitor Market Forecast 2024-2034: Analyzes Trends Likely to Shape Future Opportunities

March 14, 2024 | finance.yahoo.com

Exploring the FcRn Inhibitor Market Landscape, 2024: Market Insights, Pipeline Analysis, Expert Perspectives, and Future Trends to 2034

January 10, 2024 | seekingalpha.com

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

January 10, 2024 | tmcnet.com

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

December 19, 2023 | finance.yahoo.com

Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board

December 13, 2023 | finance.yahoo.com

Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University

December 4, 2023 | tmcnet.com

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

November 14, 2023 | markets.businessinsider.com

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

November 7, 2023 | finance.yahoo.com

Cardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023

October 16, 2023 | businesswire.com

Antiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer Therapeutics

September 5, 2023 | benzinga.com

Nykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical Cancer

May 18, 2023 | finanznachrichten.de

Trueline Therapeutics Inc.: Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810

May 18, 2023 | businesswire.com

Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810

May 17, 2023 | marketwatch.com

Corrosion Inhibitor for Oil and Gas Market | Worldwide Industry Trends 2023-2030

May 17, 2023 | marketwatch.com

Wax Inhibitor Market 2023 Fastest Growing Industry in Advanced Material Market by 2030

April 20, 2023 | wsj.com

Inhibitor Therapeutics Inc.

April 4, 2023 | msn.com

Oncternal Therapeutics Announces Strategic Reprioritization, Stops Two Zilovertamab Studies

April 4, 2023 | uk.finance.yahoo.com

iOmx Therapeutics Announces Dosing of First Patient with SIK Inhibitor OMX-0407 in Phase I Clinical Trial

March 31, 2023 | marketwatch.com

2023-2029 Medical FLT3 Inhibitor Market Share and Growth Insights | Latest Research Report

March 25, 2023 | marketwatch.com

Norepinephrine Reuptake Inhibitor Market Share by 2031

March 24, 2023 | marketwatch.com

Proton Pump Inhibitor Drug Market with Latest Technology Estimate up to 2030

March 24, 2023 | marketwatch.com

PAA Scale Inhibitor Market Top Players By 2031

See More Headlines

Receive INTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/29/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:INTI
CUSIP: N/A
CIK: 1042418
Web: www.inhibitortx.com
Phone: (888) 841-6811
Fax: 813-527-0500
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-3,030,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -45.51%
Return on Assets: -30.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.46
Quick Ratio: 13.46

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.03 per share
Price / Book: 2.28

Miscellaneous

Outstanding Shares: 171,970,000
Free Float: 164,057,000
Market Cap: $11.78 million
Optionable: Not Optionable
Beta: -0.84

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Francis E. O'Donnell Jr. (Age 74)
M.D., Founder, Executive Chairman & CEO
Comp: $600k
Mr. James A. McNulty CPA (Age 74)
Interim CFO, Treasurer & Secretary
Comp: $205.4k

Key Competitors

View All Competitors

INTI Stock Analysis - Frequently Asked Questions

How have INTI shares performed in 2024?: Inhibitor Therapeutics' stock was trading at $0.0920 on January 1st, 2024. Since then, INTI shares have decreased by 25.5% and is now trading at $0.0685.
View the best growth stocks for 2024 here.
Are investors shorting Inhibitor Therapeutics?: Inhibitor Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 500 shares, an increase of 400.0% from the March 15th total of 100 shares. Based on an average daily volume of 37,200 shares, the days-to-cover ratio is presently 0.0 days.
View Inhibitor Therapeutics' Short Interest.
When is Inhibitor Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our INTI earnings forecast.

How were Inhibitor Therapeutics' earnings last quarter?: Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) announced its earnings results on Friday, March, 29th. The company reported ($0.01) earnings per share (EPS) for the quarter.
How do I buy shares of Inhibitor Therapeutics?: Shares of INTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:INTI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial